Cart
sales@molnova.com
Thiabendazole
CAS No. 148-79-8
Thiabendazole( NSC 90507 | NSC 525040 | TBZ | Tiabendazole )
Catalog No. M12054 CAS No. 148-79-8
Thiabendazole is an Antihelminthic. Hiabendazole is a benzimidazole compound that acts as a fungicide and is reported to have aneugenic effects.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 500MG | 37 | In Stock |
|
| 1G | 48 | In Stock |
|
Biological Information
-
Product NameThiabendazole
-
NoteResearch use only, not for human use.
-
Brief DescriptionThiabendazole is an Antihelminthic. Hiabendazole is a benzimidazole compound that acts as a fungicide and is reported to have aneugenic effects.
-
DescriptionThiabendazole is an Antihelminthic. Hiabendazole is a benzimidazole compound that acts as a fungicide and is reported to have aneugenic effects.
-
In Vitro——
-
In Vivo——
-
SynonymsNSC 90507 | NSC 525040 | TBZ | Tiabendazole
-
PathwayCytoskeleton/Cell Adhesion Molecules
-
TargetMicrotubule/Tubulin
-
RecptorTubulin β
-
Research AreaInfection
-
Indication——
Chemical Information
-
CAS Number148-79-8
-
Formula Weight201.25
-
Molecular FormulaC10H7N3S
-
Purity>98% (HPLC)
-
SolubilityEthanol: 1 mg/mL (4.96 mM); DMSO: 40 mg/mL (198.75 mM)
-
SMILESC1(C2=NC3=CC=CC=C3N2)=CSC=N1
-
Chemical Name4-(1H-1,3-benzodiazol-2-yl)-1,3-thiazole
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Cha, HJ, et al. PLoS Biology, 2012, Aug, 10 (8).
molnova catalog
related products
-
Paclitaxel
Paclitaxel is a novel antineoplastic agent, which was discovered in a screen of extracts of thousands of plants and natural products for antineoplastic activity by a National Y Institute program.
-
Ombrabulin
A novel combretastatin A-4 derivative and tubulin polymerization inhibitor that strongly stanches tumour blood flows and inhibits growth of tumours developing in various tissues and organ.
-
PST-1P
PST-1P is a photoswitchable inhibitor of microtubule with EC50 of 0.7 uM under 390 nm irradiation in the MDA-MB-231 human breast cancer cell lines.
